title: Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results.
abstract: BACKGROUND
  The European tacrolimus versus ciclosporin A microemulsion (CsA-ME) renal transplantation study showed that tacrolimus was significantly more effective in preventing acute rejection and had a superior cardiovascular risk profile at 6 months.
  
  
  METHODS
  The endpoints of this investigator-initiated, observational, 36-month follow-up were acute rejection incidence rates, rates of patient and graft survival and renal function. An additional analysis was performed using the combined endpoints BPAR, graft loss and patient death. Data available from the original ITT population (557 patients; 286 tacrolimus and 271 CsA-ME) were analysed.
  
  
  RESULTS
  A total of 231 tacrolimus and 217 CsA-ME patients participated. At 36 months, Kaplan-Meier-estimated BPAR-free survival rates were 78.8% in the tacrolimus group and 60.6% in the CsA-ME group, graft survival rates were 88.0% and 86.9% and patient survival rates were 96.6% and 96.7%, respectively. The estimated combined endpoint-free survival rate was 71.4% with tacrolimus and 55.4% with CsA-ME (P <or= 0.001, chi-square test). Significantly more CsA-ME patients crossed over to tacrolimus during the 3-year follow-up: 21.2% versus 2.6%, P <or= 0.0001, chi-square test. Most patients in the tacrolimus arm discontinued steroids and received monotherapy and fewer tacrolimus patients remained on a triple regimen. Mean serum creatinine concentration was 145.4 +/- 90.9 micromol/L with tacrolimus and 149.0 +/- 92.1 micromol/L with CsA-ME. Significantly more CsA-ME patients had a classified cholesterol value >6 mmol/L (26.3% versus 12.6%, P <or= 0.0003, chi-square test).
  
  
  CONCLUSIONS
  Patients treated with tacrolimus had significantly higher combined endpoint-free survival rates and lower acute rejection rates with less immunosuppressive medication at 36 months.
authors.affiliation: Klinik und Poliklinik für Innere Medizin II--Nephrologie, Klinikum der Universität Regensburg, Germany. bernhard.kraemer@klinik.uni-regensburg.de
authors.forename: Bernhard K
authors.initials: BK
authors.lastname: Krämer
authors.forename: Domingo
authors.initials: D
authors.lastname: Del Castillo
authors.forename: Raimund
authors.initials: R
authors.lastname: Margreiter
authors.forename: Heide
authors.initials: H
authors.lastname: Sperschneider
authors.forename: Christoph J
authors.initials: CJ
authors.lastname: Olbricht
authors.forename: Joaquín
authors.initials: J
authors.lastname: Ortuño
authors.forename: Urban
authors.initials: U
authors.lastname: Sester
authors.forename: Ulrich
authors.initials: U
authors.lastname: Kunzendorf
authors.forename: Karl-Heinz
authors.initials: KH
authors.lastname: Dietl
authors.forename: Vittorio
authors.initials: V
authors.lastname: Bonomini
authors.forename: Paolo
authors.initials: P
authors.lastname: Rigotti
authors.forename: Claudio
authors.initials: C
authors.lastname: Ronco
authors.forename: Jose M
authors.initials: JM
authors.lastname: Tabernero
authors.forename: Manuel
authors.initials: M
authors.lastname: Rivero
authors.forename: Bernhard
authors.initials: B
authors.lastname: Banas
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Mühlbacher
authors.forename: Manuel
authors.initials: M
authors.lastname: Arias
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Montagnino
mesh_terms: D000328:Adult; D001706:Biopsy; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation; D008875:Middle Aged; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus